loading

About Us

History

2022

05.

KFDA Orphan Drug Designation in development stage

04.

Series A-bridge Investment

03.

U.S. FDA Orphan Drug Designation(ODD)

2021

11.

PSC Phase II First Patient Dosing

07.

Co-R&D Contract (YungJin Pharm)

03.

HQ relocation (Osong) / Series A (Institutional Investment)

01.

PSC Phase II IND Approval (KFDA)

2020

10.

Company Name Changed to CUROME BIOSCIENCES

06.

Patent Transfer Contract
(Konkuk Univ Industry-Univ Cooperation Foundation)

03.

Seed Investment / R&D Center opened (Gwanggyo)

2019

11.

Selected for TIPS program

10.

Chungbuk Creative Economy Innovation Center Investment

05.

Patent Transfer Contract
(Chungnam Univ. Industry-Univ. Cooperation Foundation)

2018

11.

Patent Acquisition and Technology Transfer Contract (Yungjin Pharm)

10.

Korea Venture Investment

2017

11.

Accredited as an affiliated R&D Center

08.

Venture Company Certification

04.

Incorporation (Huen)